Lindsay Holtz, MD
Rheumatology · Mechanicsville, VANPI 1386965150
Payments from drug & device makers
Across 520 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- Pfizer$1K
- UCB, Inc.$982
- Novartis$735
- Johnson & Johnson$715
- plus $3K from 32 others
What the payments were for
- Food & beverage$9,73499%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $1,542 |
| Amgen(2 entities) | 64 | $1,337 |
| Pfizer | 81 | $1,147 |
| UCB, Inc. | 56 | $982 |
| Novartis | 33 | $735 |
| Johnson & Johnson | 39 | $715 |
| Lilly USA, LLC | 25 | $546 |
| E.r. Squibb & Sons, L.L.C. | 27 | $464 |
| GSK | 17 | $297 |
| AstraZeneca(2 entities) | 13 | $278 |
| Genentech USA, Inc. | 18 | $275 |
| Mallinckrodt Hospital Products Inc. | 8 | $228 |
| Cumberland Pharmaceuticals, Inc. | 2 | $123 |
| Sandoz | 5 | $110 |
| Organon | 5 | $101 |
| ANI Pharmaceuticals, Inc. | 4 | $100 |
| Bristol Myers Squibb | 6 | $100 |
| Sanofi | 3 | $82 |
| Aurinia Pharma U.S., Inc. | 4 | $74 |
| Radius Health, Inc. | 2 | $60 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $56 |
| Sobi, Inc | 2 | $49 |
| Pacira Pharmaceuticals Incorporated | 2 | $37 |
| Boehringer Ingelheim | 1 | $31 |
| Mylan Institutional Inc. | 1 | $30 |
| Fresenius Kabi USA, LLC | 2 | $28 |
| Medexus Pharma, Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Sebela Pharmaceuticals Inc. | 1 | $19 |
| Octapharma USA, Inc. | 1 | $15 |
| Forte Bio-pharma LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
How this compares
$9,807 in reported general payments places this provider in the 70th percentile of 159 rheumatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 54 | $495,687 |
| Humira(Cf) PenAdalimumab | 44 | $417,206 |
| SimponiGolimumab | 25 | $191,068 |
| RinvoqUpadacitinib | 18 | $138,741 |
| Humira(Cf)Adalimumab | 17 | $133,095 |
| Yuflyma(Cf) Autoinject (2 Pck)Adalimumab-Aaty | 14 | $107,171 |
| Hydroxychloroquine Sulfate | 375 | $18,021 |
| MethotrexateMethotrexate Sodium | 405 | $14,665 |
| Leflunomide | 146 | $11,435 |
| Diclofenac Potassium | 69 | $3,853 |
| Celecoxib | 33 | $3,646 |
| Sulfasalazine | 73 | $3,290 |
| Colchicine | 35 | $3,175 |
| Leucovorin Calcium | 135 | $2,109 |
| Prednisone | 316 | $2,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,542 | $271,83635 claims |
| Johnson & JohnsonSimponi | $715 | $191,06825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 159 rheumatology providers in Virginia.
Other rheumatology in Mechanicsville
- Peter LipskyCharlottesville$1.6M
- Sharukh ShroffDanville$1.5M
- Kristi MizelleNewport News$1.2M
- Phillip KempfArlington$467K
- Adegbenga BankoleRoanoke$355K
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Michael CannonVirginia Beach$145K
- Phong NguyenReston$127K
- Roger LidmanChesapeake$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.